Is ResMed Stock Underperforming the Nasdaq?

ResMed's stock performance has been a point of concern as it lags behind the Nasdaq index. Analysts are questioning the company's growth strategy and its ability to compete in a rapidly evolving healthcare technology market. The article highlights potential challenges in ResMed's product pipeline and increased competition from both established players and startups. Investor sentiment appears cautious, with some analysts recommending a hold on the stock. Overall, the article raises concerns about ResMed's future profitability and market position.